๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Glasgow
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Glasgow

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 2852 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
2852
Studies in scope
industry-sponsored, all four open statuses
1378
Recruiting now
open to new participants
540
Lead sponsors
across recruiting studies
Top sites
London 99 Manchester 39 Cambridge 26 Glasgow 23 Bristol 17
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca34 Merck Sharp & Dohme LLC23 Pfizer17 Hoffmann-La Roche16 Novartis Pharmaceuticals15 Clear sponsor filter
Site city
London99 Manchester39 Cambridge26 Glasgow23 Bristol17
All 91 cities
Target enrolment
to
23 of 2852 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
NCT07405164Von Hippel-Lindau Disease, Malignant Neoplasms
Merck Sharp & Dohme LLC
Phase 3
450
Glasgow, London, Manchester
2026-03-23
Recruiting
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
NCT07049926Renal Cell Carcinoma
Merck Sharp & Dohme LLC
Phase 1/2
140
Edinburgh, Glasgow, London, Cardiff, Manchester
2025-07-20
Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504Endometrial Cancer
Merck Sharp & Dohme LLC
Phase 3
1,123
East Sussex, Cambridge, Glasgow, London, Edinburgh, Leicester, Maidstone, Manchester
2025-05-22
Active, closed
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)
NCT06925750Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC
Phase 2
130
Cambridge, London, Glasgow
2025-05-12
Recruiting
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
NCT06833073Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ
Merck Sharp & Dohme LLC
Phase 2
308
Glasgow, London, Torquay
2025-03-11
Recruiting
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
NCT06686394Breast Neoplasms, Breast Cancer
Merck Sharp & Dohme LLC
Phase 1/2
81
London, Glasgow
2025-02-26
Active, closed
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
NCT06459180Cervical Cancer
Merck Sharp & Dohme LLC
Phase 3
686
London, Sutton, Glasgow, Leeds, Manchester
2024-07-24
Recruiting
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
NCT06353386Prostatic Neoplasms, Castration-Resistant
Merck Sharp & Dohme LLC
Phase 1/2
220
Cambridge, Glasgow, Preston, London, Birmingham
2024-05-20
Active, closed
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
NCT06307431Renal Cell Carcinoma
Merck Sharp & Dohme LLC
Phase 2
272
Cambridge, Glasgow, London, Edinburgh, Manchester
2024-04-10
Active, closed
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
NCT06305767Bladder Cancer
Merck Sharp & Dohme LLC
Phase 1/2
230
Torquay, London, Glasgow, Manchester
2024-03-28
Recruiting
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
NCT06136624Prostate Cancer Metastatic
Merck Sharp & Dohme LLC
Phase 3
1,310
Cambridge, Truro, Glasgow, London, Manchester
2023-12-31
Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
Merck Sharp & Dohme LLC
Phase 3
1,314
Cambridge, Derby, Torquay, Northwood, Truro, Glasgow, London, Oxford
2023-12-18
Active, closed
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT06132958Endometrial Cancer
Merck Sharp & Dohme LLC
Phase 3
710
East Sussex, Derby, London, Truro, Glasgow, Manchester
2023-12-06
Active, closed
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
NCT05239728Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 3
1,800
London, Nottingham, Glasgow, Manchester, Swansea
2022-03-15
Active, closed
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
NCT05173987Endometrial Neoplasms
Merck Sharp & Dohme LLC
Phase 3
280
Manchester, Glasgow, London
2022-02-03
Recruiting
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2ฮฑ Related Genetic Alterations (MK-6482-015)
NCT04924075Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor
Merck Sharp & Dohme LLC
Phase 2
355
Cambridge, London, Glasgow
2021-08-12
Active, closed
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).
NCT04895722Colorectal Cancer
Merck Sharp & Dohme LLC
Phase 2
302
Glasgow, London-Camden, Cardiff, Coventry
2021-06-25
Recruiting
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
NCT07218029Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC
Phase 3
815
Cambridge, Glasgow, London, Newcastle upon Tyne, Sheffield
2021-05-12
Active, closed
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
NCT04634877Endometrial Neoplasms
Merck Sharp & Dohme LLC
Phase 3
990
Bristol, Cottingham, Glasgow, London, Sutton, Leicester, Manchester
2021-01-10
Active, closed
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
NCT04626518Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 1/2
370
Southampton, Glasgow, Preston, Leicester, London, Edinburgh, Cardiff, Manchester
2020-12-17
Active, closed
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
NCT04626479Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 1/2
400
Southampton, Glasgow, Preston, Leicester, London, Edinburgh, Cardiff, Manchester
2020-12-16
Active, closed
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
NCT04195750Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 3
755
Cambridge, Edinburgh, Glasgow, London, Sutton, Gillingham, Manchester
2020-02-27
Recruiting
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
NCT03486873Solid Tumors, Hematologic Malignancies
Merck Sharp & Dohme LLC
Phase 3
3,500
Aberdeen, Cambridge, Edinburgh, Manchester, Sheffield, Broomfield, Glasgow, Preston
2018-08-21
Rows per page Showing 1–23 of 23
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 18 September 2026. https://priyalifescience.com/clinical-trials-uk/city/glasgow

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.